For #Media #Investors #Attendees Synairgen has been selected as a Showcase company at the American Thoracic Society (ATS) 2023 Respiratory Innovation Summit (RIS) Join us on-site on 19-20 May in Washington DC. rb.gy/5rpvu

For #Media #Investors #Attendees Attending #ATS2023? Join our VP Non-Clinical Operations, Victoria Tear on Saturday, May 20th for an oral presentation and poster at Marriott Marquis Washington DC at 2:00pm ET rb.gy/991c5

For #Media #Investors #Attendees Type 1 interferons (such as IFN-β) have an essential role in maintaining a balanced immune response. Join our VP Non-Clinical Operations, Victoria Tear at #ATS2023 on Monday, May 22, 2023 at 11:30am EDT To learn more rb.gy/syce4

For #Attendees #Media #Investors First day #ATS2023. Our VP Non-Clinical Operations, Victoria Tear is presenting at ATS 2023 Respiratory Innovation Summit (RIS) on Saturday, May 20th at 2:00pm ET rb.gy/991c5 and on May 22nd at 11:30am ET rb.gy/syce4

For #Attendees #Media #Investors Today, our VP Non-Clinical Operations, Victoria Tear is presenting 'Clinical Development of Inhaled IFN-β In COVID-19 Patients in the Home and Hospital Settings' at #ATS2023 at 11:30am ET rb.gy/syce4

For #Media #investors Missed us at the ATS Respiratory Innovation Summit and our poster presented by VP Non-Clinical Operations, Victoria Tear, at #ATS2023? The poster is available on our website rb.gy/idj4x

For #Media #Investors With the autumn respiratory virus season approaching, CSO Dr Phillip Monk wrote a column on the need for new broad spectrum #antiviral therapies to support vulnerable populations and the fact that not all antivirals are the same. shorturl.at/owCIZ

For #Media #Attendees This weekend our Chief Scientific Officer Dr. Phillip Monk, presented data offering an overview of our trials in COVID-19 patients at ERS International Congress. #ERS2023 #SNG #presentation

For #investors #media This morning we published our interim statement of unaudited results for the six months ended 30 June 2023. Read the statement on our website: synairgen.com/media/interim-… #SNG #FinancialResults

For #media #investors Our CEO Richard Marsden spoke with Proactive following the announcement of our interim results this morning. Watch the interview below.

For #Media Dr. Marcin Mankowski joins Synairgen today as full-time #CMO. Marcin brings extensive experience as a seasoned pharmaceutical physician and drug developer. synairgen.com/media/synairge… #appointment #SNG #clinicaltrial #antivirals

For #Media #Attendees #Investors Join our CSO Phillip Monk this Thursday at 12:15pm ET in the Poster Hall, as he presents data from our Phase 2 trial in COPD patients with respiratory infections at IDWeek. #SNG

For #Media #Investors Joseph Colliver joins Synairgen as #CFO effective 6 Nov. Following 20 years of loyal service, John Ward will step down on the same date. Joseph brings extensive financial leadership experience in CFO positions across the life sciences tinyurl.com/22vzuc5b

For #Media #Investors The positive data from the US NIH-led ACTIV-2 Phase 2 trial for our investigational drug SNG001 were published this week in eClinicalMedicine. Read the full publication: thelancet.com/journals/eclin… #Publication #COVID19 #SNG

For #Media #Investors Data from our SG015 randomised, placebo-controlled Phase 2 clinical study in COPD patients, have been published in the Oxford Academic Journal’s Open Forum Infectious Diseases. academic.oup.com/ofid/article/1… #Publication #SNG

For #Attendees #Media Our Chief Scientific Officer Phillip Monk will be presenting a poster at the American Thoracic Society (ATS) conference on Monday, 20 May in San Diego at 9:15 AM PDT in Area H (Hall H, Ground Level). #ATS2024 #SNG #PosterPresentation

For #Media #Investors Data from our two-part Phase 2 SG015 trial exploring the potential of SNG001 has been published in Respiratory Research, a Springer Nature publication. Read more on the data: link.springer.com/article/10.118… #COPD #SNG #Publication

For #media #investors: This morning we published our preliminary statement of audited results for the year ended 31 December 2023 and our Annual Report. Read the results statement here: synairgen.com/media/results-… Read the Annual Report here: synairgen.ams3.digitaloceanspaces.com/240627-Synairg… #SNG

For #media #investors: Richard sat down with Proactive to provide some commentary on today’s results and the rationale behind its planned trial in mechanically ventilated patients. Watch the full interview here: youtube.com/watch?v=WKXgYt…

For #media #investors: This morning we published our interim statement of unaudited results for the six months ended 30 June 2024. Read the statement on our website: synairgen.com/media/interim-… #SNG